Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment candidate for newly diagnosed, relapsed or refractory multiple myeloma. Through this partnership, researchers will test clonoSEQ’s ability to both measure minimal residual disease (MRD) and determine the clinical value of monitoring MRD in isatuximab-treated patients. “MRD status is being...Continue Reading
The addition of elotuzumab (Empliciti) to pomalidomide (Pomalyst) and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma, according to findings from the phase II ELOQUENT-3 trial reported at the 2018 EHA Congress. Median progression-free survival (PFS) was 10.3 months (95%...Continue Reading
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study Moreau, Mateos, Berenson, Weisel, Lazzaro, Song, Dimopoulos, Huang, Zahlten-Kumeli & Stewart. Lancet Oncol, June 2018. Background Twice a week carfilzomib at 27 mg/m² is approved for treatment of relapsed or...Continue Reading
Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients with relapsed/refractory multiple myeloma (RRMM), according to a study published in The Lancet Haematology.1 Carfilzomib twice weekly is currently approved for the treatment of RRMM but is associated with significant burden to both patients and caregivers as treatment...Continue Reading
CHICAGO (Reuters) – Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. Nick Leschly, CEO of bluebird, speaks in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer The treatment, called...Continue Reading
CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. The treatment, called bb2121, belongs to a hot new therapy class called CAR-T that harvests a patient’s own disease-fighting T-cells, genetically modifies them in...Continue Reading
When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine the most effective treatment method, according to Jeffrey Wolf, M.D. While many physicians in the oncology space have shortened the disease’s name by simply saying “myeloma”, Wolf – who is a clinical...Continue Reading
CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Dr Rob Weinkove spoke at our patient seminar on CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment. Watch the seminar here:Continue Reading
